Welcome to our dedicated page for PUMA BIOTECHNOLOGY SEC filings (Ticker: PBYI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Puma Biotechnology SEC filings document an oncology biopharmaceutical business whose reported net product revenue comes from sales of NERLYNX®, its commercial oral neratinib product for HER2-positive breast cancer. Form 8-K reports furnish quarterly and annual operating results, financial-condition updates and exhibit press releases, including disclosures on revenue categories, cost of sales and guidance.
Proxy materials cover board matters, executive compensation and equity-award information, while material-event filings record governance actions such as amendments to the company’s bylaws. The filing record also provides formal context for common stock listed on the Nasdaq Global Select Market and development disclosures related to alisertib and Puma’s oncology programs.
Puma Biotechnology, Inc. reported Q2 2026 total revenue of $56,502 (thousands), up from $52,436 (thousands) a year earlier, driven by product revenue of $53,560 (thousands) and royalty revenue of $2,942 (thousands). Q2 net income was $8,189 (thousands), compared with $5,855 (thousands) in Q2 2025, with diluted EPS of $0.16.
For the first six months of 2026, revenue was $101,316 (thousands) and net income was $4,436 (thousands). As of June 30, 2026, total assets were $192,736 (thousands), including cash, cash equivalents and marketable securities totaling approximately $93.9 million, and stockholders’ equity was $138,544 (thousands). Long-term debt was reduced to $0 after repayment of the Athyrium Notes, while the company continues to commercialize NERLYNX® and develop alisertib. Management believes existing liquidity and expected cash flows are sufficient to meet operating needs for at least one year after this Form 10-Q is filed, while noting potential uncertainty from new U.S. pharmaceutical import tariffs.
Puma Biotechnology reported results for the quarter ended June 30, 2026 and raised its 2026 revenue and net income guidance, citing increased demand for NERLYNX. Total revenue for the quarter was $56.5 million, including NERLYNX net product revenue of $53.6 million, up from $52.4 million and $49.2 million in the prior-year quarter. GAAP net income rose to $8.2 million, or $0.16 per basic and diluted share, from $5.9 million, while non-GAAP adjusted net income increased to $10.1 million.
For the first six months of 2026, total revenue was $101.3 million and GAAP net income was $4.4 million, down from $8.8 million, as operating costs grew to support alisertib clinical programs; R&D expenses rose to $38.7 million from $29.3 million. Cash, cash equivalents and marketable securities were $93.9 million at June 30, 2026, and outstanding debt was reduced to zero after the final payment under the 2021 Note Purchase Agreement. The company now guides 2026 total revenue to $224–$231 million and net income to $17–$20 million, and highlights multiple upcoming milestones in its ALISCA alisertib Phase II trials in breast and small cell lung cancer.
Puma Biotechnology President and CEO Alan H. Auerbach reported an open-market sale of 44,058 shares of common stock at $8.263 per share on July 6, 2026. After this transaction, he still directly holds 7,261,671 shares, suggesting it represents a small portion of his stake. The sale was executed under a pre-established Rule 10b5-1(c) sell-to-cover program adopted on December 17, 2020, indicating it was part of a pre-planned trading arrangement.
PUMA Biotechnology officer Douglas M. Hunt reported an open-market sale of company stock. On the reported date, he sold 8,460 shares of PUMA Biotechnology common stock at an average price of $8.263 per share. After this transaction, he directly holds 196,841 shares of common stock. The filing notes that the sale occurred under a Rule 10b5-1(c) sell-to-cover program adopted on December 14, 2020, indicating the trade was executed pursuant to a pre-arranged trading plan.
PUMA Biotechnology Chief Financial Officer Maximo F. Nougues sold 9,386 shares of common stock on July 6, 2026 in an open-market transaction at an average price of $8.263 per share. After this sale, he directly holds 230,637 shares of the company’s common stock.
The transaction was executed under a pre-arranged Rule 10b5-1(c) sell-to-cover program, originally adopted on December 14, 2020, indicating it followed a preset trading plan rather than discretionary market timing.
Puma Biotechnology, Inc. reported the results of its annual shareholder meeting. Stockholders elected eight directors, with each nominee receiving more votes "For" than "Withheld." Alan H. Auerbach received 37,130,678 votes "For" and 785,624 "Withheld," while other nominees showed similar support levels.
Shareholders also voted on three additional proposals. One proposal drew 42,612,940 votes "For" and 1,328,476 "Against". Another received 29,326,673 votes "For" and 7,878,580 "Against." A further proposal received 18,234,150 votes "For" and 19,596,238 "Against," indicating it did not obtain majority support.
Puma Biotechnology director Troy Edward Wilson reported both a stock grant and a sale of shares of common stock. He received 27,000 Restricted Stock Units (RSUs) that vest in full on the earlier of one year from grant or the next annual shareholder meeting, subject to his continued service with the company.
Wilson also completed an open-market sale of 10,800 shares at a weighted average price of $7.1989 per share under a pre-arranged Rule 10b5-1(c) trading plan adopted on 03-12-2025. Following these transactions, he holds 59,750 shares directly, plus 550 shares indirectly through accounts for two children.